AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03158090 — intervention group
Intervention type: RADIATION
Intervention: radiotherapy
Description: The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
Study NCT00962468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COPD evidence based care pathway
Description: A care pathways, as complex intervention, will be implemented.
Study NCT04645966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent rLP2086 (60-µg Dose)
Description: Trumenba (half dose) - Meningococcal Group B vaccine
Study NCT04645966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bivalent rLP2086 (120-µg Dose)
Description: Trumenba - Meningococcal Group B vaccine
Study NCT04356872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: immune check point inhibitor, 200mg, iv, d1
Study NCT04356872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: ADM, 60mg/m2, iv, d1
Study NCT04356872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: IFO, 1.8 g/m2/d, d1-5
Study NCT02130752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monopolar electrocautery
Description: During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
Study NCT02130752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Description: During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
Study NCT03024710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention cluster
Description: The mother- infant pairs (the infant who has completed his/her 6 month of age from the date of birth along with their mother) of intervention clusters will receive the CF practice counselling in groups as soon as enrolment is completed by CHRW at fixed site clinic and refreshers will be arranged 3 months apart from first training in groups at same place and by same person. However CHRWs will also counsel each participant during her bimonthly household visit.
Study NCT02959697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcut. + Subconj. Xylocaine
Description: Patient will receive the standard subcutaneous local anesthetic as well as an additional subconjunctival injection of local anesthetic (Xylocaine).
Study NCT02959697 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Subcut. + Sham Subconj. Injection
Description: Patient will receive the standard subcutaneous local anesthetic as well as a subconjunctival sham injection of Normal Saline.
Study NCT02959697 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Blepharoptosis Repair
Description: Patients will undergo blepharoptosis repair using an anterior approach.
Study NCT02959697 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blepharoptosis Repair
Description: Patients will undergo blepharoptosis repair using an anterior approach.
Study NCT05810389 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride
Description: Application methods of delivery of topical fluoride
Study NCT05810389 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fluoride
Description: Application methods of delivery of topical fluoride
Study NCT04645966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero
Description: Bexsero - Meningococcal Group B vaccine
Study NCT04645966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic Liquid Paracetamol (PLP)
Description: PLP administration during primary vaccinations 1 and 2
Study NCT04645966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: Nimenrix - Meningococcal Group A, C, W and Y vaccine
Study NCT04645966 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline
Study NCT04599062 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
Study NCT04599062 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
Study NCT04430179 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]
Description: 300 mg every other week for 24 weeks
Study NCT04430179 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active drug
Study NCT02411448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV.
Study NCT02411448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study NCT02411448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Erlotinib
Description: Administered orally.
Study NCT02411448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Administered orally.
Study NCT01966653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrofurantoin
Description: nitrofurantoin 100 mg po tid for 5 days
Study NCT02411448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Administered orally.
Study NCT02411448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Administered orally.
Study NCT03309033 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT03309033 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study NCT01966653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosfomycin
Description: fosfomycin 3g po single dose
Study NCT05209958 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil Lynphosite ratio
Description: The patients were divided into 2 groups as NLR level above 2 (Group A) (n:32) and NLR level below 2 (Group B) (n:28).
Study NCT01144091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxyphylline
Description: pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
Study NCT01144091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
Study NCT04645966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scheduled Liquid Paracetamol (SLP)
Description: SLP administration after primary vaccinations 1 and 2.
Study NCT04645966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Therapeutic Liquid Paracetamol (TLP)
Description: TLP administration after primary vaccinations 1 and 2
Study NCT02445274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior lens capsule was reserved
Description: The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
Study NCT03748030 — intervention group
Intervention type: RADIATION
Intervention: Confirmed Left-Sided Breast Cancer
Description: Left-Sided Patients will receive standard radiation therapy, including 42.5 Gy in 16 fractions or 50 Gy in 25 fractions.
Study NCT03433898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754091
Description: Solution for infusion
Study NCT03433898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 754111
Description: Solution for infusion
Study NCT02875015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: 20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars
Study NCT02875015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride and Lidocaine
Description: Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
Study NCT02875015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suburethral Sling
Description: A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
Study NCT02875015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suburethral Sling
Description: A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
Study NCT01878461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Study NCT01878461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M518101
Study NCT04642651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Patients in the dexmedetomidine group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and 1.0 μg/kg dexmedetomidine, in a total volume of 20 ml.
Study NCT04642651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
Study NCT01316302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pristiq
Description: Flexible dose, 50-100mg QD, for 12 weeks.
Study NCT01316302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, taken QD for 12 weeks.
Study NCT03891030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Checklist Based Box system intervention
Description: The intervention has both behavioural change and service utilization drop out tracing mechanism. Special type of boxes designed to schedule health educations and continued service utilization monitoring boxes will be placed at health posts and health centers respectively. Community level survey will be conducted to identify suspected pregnant mothers using stanback et al, 1999 checklist, and mothers are linked to health centers. Then, they will be followed for their subsequent attendance of consecutive maternal health services (ANC 2nd-third PNC). Mothers who fail to utilize the service will be traced; will get person-centered health education to continue the service.
Study NCT04391530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: emotional freedom technique, breathing therapy
Description: emotional freedom technique, breathing therapy
Study NCT01490983 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: no access to eMedonline
Description: patients will be followed for 3 months but will not use eMedonline
Study NCT01490983 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eMedonline access
Description: patients will be given access to eMedonline use for 3 months
Study NCT01144091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxiphylline
Description: pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
Study NCT01449097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor-Canal-Blockade
Description: US-guided Adductor-Canal-blockade with Ropivacaine
Study NCT01449097 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: The femoral nerve block
Description: US-guided femoral nerve block with ropivacaine
Study NCT01449097 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: US-guided Adductor-Canal-Blockade/femoral nerve block with saline
Study NCT03052868 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cognitive Assessment
Description: Cognitive testing session
Study NCT05396261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Film forming silicone gel (7-0940)
Description: Anecdotal evidence suggests that genital conditions in women associated with vaginal atrophy improve with the use of film-forming silicone dressings.
Study NCT00142233 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ANTOX (vers.)1.2
Description: 300 µg organic selenium, 720 mg vitamin C, 228 mg vitamin E, 2880 mg methionine per day (for patients of 10 years and older)~150 µg organic selenium, 360 mg vitamin C, 114 mg vitamin E, 1440 mg methionine per day (for patients aged between 5 and 9 years)
Study NCT00142233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium
Description: 15 mmol per day (for patients of 10 years and older)~7,5 mmol per day (for patients aged between 5 and 9 years)
Study NCT00142233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo ANTOX (vers)1.2
Description: Placebo ANTOX (vers)1.2
Study NCT00142233 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ANTOX (vers)1.2
Description: Placebo ANTOX (vers)1.2
Study NCT00142233 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Magnesiocard (2.5 mmol)
Description: Placebo Magnesiocard (2.5 mmol)
Study NCT00142233 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Magnesiocard (2.5 mmol)
Description: Placebo Magnesiocard (2.5 mmol)
Study NCT01119508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
Study NCT01119508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Induction Phase, 200 mg/m\^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
Study NCT04558268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.~Prednisone is used as an anti-inflammatory or an immunosuppressant medication. Prednisone treats many different conditions such as allergic disorders, skin conditions, ulcerative colitis, arthritis, lupus, psoriasis, or breathing disorders.
Study NCT04558268 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Progesterone
Description: Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy.
Study NCT04558268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone is a female hormone important for the regulation of ovulation and menstruation.~Progesterone is used to cause menstrual periods in women who have not yet reached menopause but are not having periods due to a lack of progesterone in the body. It is also used to prevent overgrowth in the lining of the uterus in postmenopausal women who are receiving estrogen hormone replacement therapy.
Study NCT03155997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally.
Study NCT00632996 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: Exercise, manual therapy, patient education, posture, home exercise program
Study NCT03600870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midodrine
Description: Midodrine is an oral alpha-1 agonist that increases vascular tone. It is administered orally. The initial starting dose will be midodrine 5mg orally three times a day. After 7-10 days, patients will increase the dose to 10mg three times a day as tolerated if no adverse effects occur. Treatment duration will be 6 months.
Study NCT01340404 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplantation
Description: Stem cell transplantation
Study NCT01340404 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transfusion program
Description: Transfusion program
Study NCT03596970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC withdrawal
Description: Everolimus (RAD001) with MMF and Steroids
Study NCT03596970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus with reduced TAC
Description: Active comparator arm: Everolimus (RAD001) with reduced TAC and Steroids
Study NCT03751969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: The first 2 subjects will receive an intravenous injection of 0.4 mg/kg of HSK3486 emulsion injection (containing \[14C\] HSK3486 at a radiation dose of 5 nCi/0.4 mg/kg, i.e. a subject with the body weight of 60 kg is administered with a radiation dose of 300 nCi). The radiation dose for subsequent subjects can be adjusted based on the results of the first 2 subjects.
Study NCT04558268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vit D
Description: Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.
Study NCT04558268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vit D
Description: Vitamin D acts on our bones, intestines, kidneys and parathyroid glands to keep calcium in balance throughout our body. Vitamin D receptors are also located within our cardiovascular system, lungs, pancreas, skeletal muscle, skin, and reproductive organs. In summary, vitamin D is a prohormone that is essential for good health.
Study NCT04558268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iron Supplement
Description: Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.
Study NCT04558268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Supplement
Description: Iron is one of the minerals in the human body. It is one of the components of hemoglobin, the substance in red blood cells that helps blood carry oxygen throughout the body.
Study NCT04558268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer.
Study NCT04558268 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Folic acid is a type of B vitamin that is normally found in foods such as dried beans, peas, lentils, oranges, whole-wheat products, liver, asparagus, beets, broccoli, brussels sprouts, and spinach.~Folic acid helps your body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer.
Study NCT04414462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exergaming training
Description: * HEADING: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TIGHTROPE TENSION: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* SNOWBOARD SLALOM: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)~* TABLE TILT: For 5 mins a day,3 days a week in first 3 weeks (beginner level game) and for 10 mins a day, 3 days a week for 3 weeks. (advanced level game)
Study NCT04414462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: training - Group II
Description: * Wobble board for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Habituation exercises for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Double leg stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Single leg stance with eyes open and eyes open on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.~* Tandem walk stance with eyes open and eyes closed on firm surface and on foam for 4 mins a day,3 days a week for first 3 weeks and for 8 mins a day,3 days a week for 3 weeks.